AbbVie  today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE) for the treatment of moderate to severe ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...